OncoMatch/Clinical Trials/NCT05195710
Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases
Is NCT05195710 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Yttrium-90 (Y-90) resin microspheres for metastases.
Treatment: Yttrium-90 (Y-90) resin microspheres — A prospective, interventional study evaluating the safety of Y-90 TARE for tumor control of the right side and induction of left liver hypertrophy as part of a planned single-stage or two-stage hepatectomy for patients with CLM and insufficient FLR at the time of presentation.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Prior therapy
Must have received: cytotoxic chemotherapy
Received at least four cycles (or two months) of chemotherapy
Lab requirements
Blood counts
Platelet count ≥100,000/µL
Liver function
Starting total bilirubin ≤1.3 mg/dL (except if patient has Gilbert's Disease); no portal hypertension and/or cirrhosis; albumin ≥3.5 g/dl
Portal hypertension and/or cirrhosis; Starting total bilirubin >1.3 mg/dL (except if patient has Gilbert's Disease); Platelet count <100,000/µL; Albumin <3.5 g/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify